Skip to main content Skip to main navigation menu Skip to site footer
Revista Medicina - Universidad Francisco Marroquín
Revista de la Facultad de Medicina

Vol. 1 No. 34 (2023)

Average parathyroid hormone level in patients with chronic kidney disease stages III to V, National Chronic Renal Patient Care Unit

Artículos científicos
DOI: https://doi.org/10.37345/23045329.v1i34.94
Published: 2023-07-28

Abstract

Despite the prevalence of chronic kidney disease in Guatemala, there are few data on the mineral and bone disorders in chronic kidney disease. An observational cross-sectional study was designed and implemented in a public health institution in Guatemala. Fifty-eight patients with chronic kidney disease in stages III, IV, and V were included to determine serum levels of creatinine, phosphorus, calcium, intact parathormone (PTH), and albumin. The main objective of the study was to determine if the average value of parathyroid hormone differs between stages IIIA, IIIB, IV and V, as well as to stage the degree of bone mineral metabolism alterations in the population studied. Regarding the stages of chronic kidney disease, 50% of patients in stage IIIB; 62% of stage IV and 95% of stage V presented results compatible with secondary hyperparathyroidism. Stage V patients were determined to have statistically different parathyroid hormone values ​​compared with stage IIIA, IIIB, and IV patients with 90% certainty (p= 6.08 x 10⁻⁶). The results of 21% of the patients demonstrated hyperphosphatemia. Hypocalcemia was found in 12% of patients.

References

  1. Eknoyan G, Lamiere N, Eckardt K, Wheeler D, Kasiske B, Abboud O, et al. KDIGo 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Off J Int Soc Nephrol. 2012;3(1).
  2. Melamed ML, Buttar R, Coco M. CKD-MBD in stage 4 and 5 CKD: What we know in 2015. Adv Chronic Kidney Dis. 2017;176(3):139–48.
  3. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53. DOI: https://doi.org/10.1038/sj.ki.5000414
  4. Waziri B, Duarte R, Naicker S. Chronic Kidney Disease Mineral and Bone Disorder. Int J Nephrol Renovasc Dis. 2019;(12):263–76. DOI: https://doi.org/10.2147/IJNRD.S191156
  5. Supplements KI. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1–59. DOI: https://doi.org/10.1016/j.kisu.2017.04.001
  6. Hruska KA, Sugatani T, J Williams M. Pathophysiology of The Chronic Kidney Disease–Mineral Bone Disorder. Encyclopedia of Bone Biology. 2020. p. 43–56. DOI: https://doi.org/10.1016/B978-0-12-801238-3.11271-1
  7. Martin KJ, Floege J, Ketteler M. 84 - Bone and Mineral Disorders in Chronic Kidney Disease [Internet]. Sixth Edition. Comprehensive Clinical Nephrology. Elsevier Inc.; 2023. 979-995.e1 p. Available from: https://doi.org/10.1016/B978-0-323-47909-7.00084-6
  8. Quinibi W. Adynamic bone disease associated with chronic kidney disease. Up To Date. 2021.
  9. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int [Internet]. 2008;73(11):1296–302. Available from: http://dx.doi.org/10.1038/ki.2008.64 DOI: https://doi.org/10.1038/ki.2008.64
  10. Bellorin-Font E, Vasquez-Rios G, Martin KJ. Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease. Curr Osteoporos Rep. 2019;17(5):333–42. DOI: https://doi.org/10.1007/s11914-019-00533-x
  11. De Boer, I. H., Gorodetskaya, I., Young, B., Hsu, C. Y., & Chertow, G. M. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. Journal of the American Society of Nephrology. 2003; 13(11), 2762–2769. https://doi.org/10.1097/01.ASN.0000034202.91413.EB DOI: https://doi.org/10.1097/01.ASN.0000034202.91413.EB
  12. Muntner P, Jones TM, Hyre AD, Melamed ML, Alper A, Raggi P, et al. Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate. Clin J Am Soc Nephrol. 2009;4(1):186–94. DOI: https://doi.org/10.2215/CJN.03050608
  13. Loaiza J, Hernández A, Sánchez Polo V. Situación De La Enfermedad Renal Crónica En Guatemala. Asoc Medica interna [Internet]. 2017;21(21):22–5. Available from: http://pdf.usaid.gov/
  14. Rosa-Diez G, Gonzalez-Bedat M, Pecoits-Filho R, Marinovich S, Fernandez S, Lugon J, et al. Renal replacement therapy in Latin American end-stage renal disease. Clin Kidney J. 2014;7(4):431–6. DOI: https://doi.org/10.1093/ckj/sfu039
  15. Nowak KL, Chonchol M. Management of Mineral and Bone Disorders in Chronic Kidney Disease [Internet]. Chronic Renal Disease. Elsevier Inc.; 2020. 1013–1033 p. Available from: http://dx.doi.org/10.1016/B978-0-12-815876-0.00062-0 DOI: https://doi.org/10.1016/B978-0-12-815876-0.00062-0
  16. Lau, W. L., Obi, Y., & Kalantar-Zadeh, K. Parathyroidectomy in the Management of Secondary Hyperparathyroidism. Clinical journal of the American Society of Nephrology. 2018; 13(6), 952–961. https://login.research4life.org/tacsgr1doi_org/10.2215/CJN.10390917 DOI: https://doi.org/10.2215/CJN.10390917
  17. Cohen, J. A Power Primer. Psychological Bulletin. 1992; 112(1), 155–159. https://doi.org/10.1038/141613a0 DOI: https://doi.org/10.1037/0033-2909.112.1.155
  18. Levey, A. S., Inker, L. A., & Coresh, J. GFR estimation: From physiology to public health. American Journal of Kidney Diseases. 2014; 63(5), 820–834. https://doi.org/10.1053/j.ajkd.2013.12.006 DOI: https://doi.org/10.1053/j.ajkd.2013.12.006
  19. Unidad Nacional de Atención al Enfermo Renal Crónico. 2016. unaerc.gob/estadísticas
  20. Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutiérrez OM, et al. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2017;70(6):737–51. DOI: https://doi.org/10.1053/j.ajkd.2017.07.019
  21. Ureña-Torres PA, Vervloet M, Mazzaferro S, Oury F, Brandenburg V, Bover J, et al. Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. Clin Kidney J. 2018;12(2):269–80. DOI: https://doi.org/10.1093/ckj/sfy061
  22. Bureo JC, Arévalo JC, Antón J, Adrados G, Jiménez Morales JL, Robles NR. Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine. Endocrinol y Nutr (English Ed [Internet]. 2015;62(7):300–5. Available from: http://dx.doi.org/10.1016/j.endoen.2015.08.007 DOI: https://doi.org/10.1016/j.endoen.2015.08.007
  23. Górriz JL, Molina P, Bover J, Barril G, Martín-de Francisco ÁL, Caravaca F, et al. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: Results of the OSERCE study. Nefrologia. 2013;33(1):46–60.
  24. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int [Internet]. 2007;71(1):31–8. Available from: http://dx.doi.org/10.1038/sj.ki.5002009 DOI: https://doi.org/10.1038/sj.ki.5002009
  25. Sethi, S., Sethi, N., Sandhu, J. S., Makkar, V., Kaur, S., Sohal, P. M., & Mehta, S. Changing Spectrum of Mineral Bone Disorder in Chronic kidney disease stage 3 to 5 D and Its Associated Factors, A Prospective Cross-Sectional Study from Tertiary Care Hospital in Northern India. Iranian journal of kidney diseases. 2021; 15(3), 199–205.
  26. Valson AT, Sundaram M, David VG, et al. Profile of incident chronic kidney disease related-mineral bone disorders in chronic kidney disease Stage 4 and 5: A hospital based cross-sectional survey. Indian J Nephrol. 2014; 24(2): 97-107. DOI: https://doi.org/10.4103/0971-4065.127897
  27. Bover J, Ureña-Torres P, Mateu S, DaSilva I, Gràcia S, Sánchez-Baya M, et al. Evidence in chronic kidney disease-mineral and bone disorder guidelines: Is it time to treat or time to wait? Clin Kidney J. 2020;13(4):513–21. DOI: https://doi.org/10.1093/ckj/sfz187

License

Copyright (c) 2023 Ana Keilhauer y Marco Antonio Peñalonzo Bendfeldt

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Authors who publish in this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License 4.0 (CC BY-NC_SA 4.0) that indicates: a) It is allowed that others share the work, with an acknowledgement of the work's authorship and initial publication in this journal, b) The work may not be used for commercial purposes, c) If it's remixed, transformed, or built upon the material, one must distribute the contributions under the same license as the original
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository, website or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
  • Ana María Keilhauer Varona
  • Marco Antonio Peñalonzo Bendfeldt
    Centro de Tiroides y Paratiroides
Palabras clave: chronic kidney disease secondary hyperparathyroidism mineral and bone disorders in chronic kidney disease parathyroid hormone

Revista de la Facultad de Medicina is an Open Access scholarly peer-reviewed journal. It aims to publish clinical research studies and clinical trials contribuiting to enrich the knowledge and development of the Medical Science. The journal is published semi-annualy by the Faculty of Medicine of Francisco Marroquin university. 

Call for papers for our following issue July - December 2022

Check if your work meet the requirements specified in the submission preparation checklist

If your work meet the requirements, register, log in y submit your work

Por favor lea todos los pasos en el arbitraje por los que tiene que pasar para llegar a la recta final

 

This work is under a Creative Commons Attribution-Non Comercial-Share Alike-4.0 Internacional License (CC BY-NC-SA 4.0)

 

 

How to Cite

Keilhauer Varona, A. M., & Peñalonzo Bendfeldt, M. A. (2023). Average parathyroid hormone level in patients with chronic kidney disease stages III to V, National Chronic Renal Patient Care Unit. Revista De La Facultad De Medicina, 1(34), 34–48. https://doi.org/10.37345/23045329.v1i34.94

Information